Status:
COMPLETED
A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma
Lead Sponsor:
Eurofarma Laboratorios S.A.
Conditions:
Asthma
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
The primary objective will be to compare the Eurofarma and Alenia formulations regarding their impact on the pulmonary function of mild to moderate persistent asthma patients and the secondary objecti...
Detailed Description
The primary objective will be to compare the Eurofarma and Alenia formulations regarding their impact on the pulmonary function of mild to moderate persistent asthma patients and the secondary objecti...
Eligibility Criteria
Inclusion
- Sign the ICF;
- ≥ 12 years old;
- Have a diagnosis of mild to moderate persistent asthma diagnosis, as per the GINA classification (www.ginasthma.com),18 with symptoms for at least 6 months and clinically stable for at least 1 month with the ACQ-7 test \<3,0;
- Current use of inhaled corticosteroid (equivalent to 1000 µg of beclomethasone dipropionate) whether associated or not with long-term β2 adrenergics and relief medication (salbutamol or equivalent);
- Initial FEV1 of at least 50% of the normal value expected;
- Serum cortisol evaluation within the normal limits
Exclusion
- Use of oral or parenteral corticosteroid within the last 3 months before the study;
- Hospitalization needed due to asthma within the last 3 months before the study;
- Active smokers, defined as the consumption of cigarettes, pipes, cigars, or any other form of smoking in any amount within the last 3 months;
- Presence of serious co-morbidities, such as cardiovascular, renal, liver, neurological, neoplastic, hematological, infectious, dermatologic, neurological, or psychiatric disease, or chronic respiratory disease other than asthma;
- Recent participation (\<6 months) or expected participation in other clinical trials involving drug products of any nature or in studies consisting of any form of intervention for the treatment of asthma;
- Intolerance or allergy to any component of the drugs evaluated in the study;
- Pregnant or lactating women;
- Chronic use of routine β-blockers orally or intravenously, including ophthalmic solutions.
Key Trial Info
Start Date :
April 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
552 Patients enrolled
Trial Details
Trial ID
NCT01167010
Start Date
April 1 2011
End Date
February 1 2012
Last Update
May 1 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro de Referencia em Enfermidades Respiratoria e Alergica
Salvador, Estado de Bahia, Brazil
2
Hospital de Clinicas UFPR
Curitiba, Paraná, Brazil
3
IMA Brasil - Instituto de Pesquisa Clínica e Medicina Avançada
São Paulo, São Paulo, Brazil
4
Stelmach Pesquisa Clinica
São Paulo, São Paulo, Brazil